Screener
Denali Therapeutics Inc. DNLI Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss | $(256,000) | $(257,089) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 6,414 | 5,370 |
| Stock–based compensation expense | 46,002 | 50,547 |
| Net accretion of discounts on marketable securities | (2,704) | (6,585) |
| Non-cash adjustment to operating lease expense | (2,353) | (2,161) |
| Right-of-use asset amortization for finance lease | 1,831 | 1,798 |
| Non-cash interest expense related to revenue participation right liability | 5,941 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s stock-based comp?
- Denali Therapeutics Inc. (DNLI) reported stock-based comp of $22.92M in Q2 2026.
- How has Denali Therapeutics Inc.'s stock-based comp changed year-over-year?
- Denali Therapeutics Inc.'s stock-based comp decreased by 9.7% year-over-year, from $25.39M to $22.92M.
- What is the long-term trend for Denali Therapeutics Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s stock-based comp has grown at a 4.0% compound annual growth rate (CAGR), from $85.25M to $99.63M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Denali Therapeutics Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude